Chinook Therapeutics Profit Margin

Chinook Therapeutics (KDNY) currently reports a profit margin of -4158.15% as of June 2023. That compares with -170.15% in the prior-year period — down 2343.9% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Chinook Therapeutics's profit margin history and peer comparisons.

Chinook Therapeutics's profit margin decreased from -170.15% to -4158.15% — a 2343.9% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chinook Therapeutics's profit margin of -4158.15% is lower than the Healthcare sector average of 14.34%. That is roughly 29087.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Chinook Therapeutics's current -4158.15% should be judged against Healthcare norms (sector average: 14.34%) and against KDNY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4158.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Chinook Therapeutics, and consider following KDNY for alerts when major investors trade the stock.